e-Drug3D

2049

FINERENONE

INN
FINERENONE

cas 1050477-31-0

CLASS

CARDIOVASCULAR
NON STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONIST (MRA)
TREATMENT OF PATIENTS WITH CHRONIC KIDNEY DISEASE ASSOCIATED WITH TYPE 2 DIABETES

ROUTE (list)

ORAL

ATC code

C03DA05

PK parameters

F 44 PERCENT
Tmax 0.8 HOUR
VD 52.6 LITER
Cl 25 LITER / HOUR
PPB 92 PERCENT
t1/2 2.5 HOUR

Solubility

PRACTICALLY INSOLUBLE IN WATER

Target

TARGET MINERALOCORTICOID RECEPTOR

DrugCentral

Mineralocorticoid receptor UNIPROT P08235

Download SDF file

1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-

Formula:
C21H22N4O3

Calculated chemical properties:

MW 378.43
NB_atoms 28
XLogP 2.99
PSA 99.706
NB_HD 3
NB_HA 7
fsp3 0.29
Lipinski(0=no;1=yes) 1

FDA
NDA 215341 (label) INN (FINERENONE) KERENDIA (BAYER HLTHCARE) APPROVAL= AP YEAR= 2021 NEWMOLECULARENTITY